Stereotaxis NASDAQ: STXS www.stereotaxis.com
NYSE: STXSSaint Louis, US · 195 employees on LinkedIn · 2 known investors
Find your way into Stereotaxis NASDAQ: STXS www.stereotaxis.com
Stereotaxis develops robotic systems for interventional medicine, focused on endovascular and cardiac procedures such as cardiac ablation. Its technology serves physicians and hospitals performing minimally invasive interventional treatments.
Founders & leadership
DL
David L. FischelinChairman & CEO
KR
Kimberly R. PeeryExecutive
PA
Paul A. BrathwaiteinDirector of Clinical Adoption Engineering2010–2012Paul A. Brathwaite is Vice President of Research and Development at Stereotaxis, where he leads development of robotic systems for cardiac and endovascular interventional procedures. He has held roles in medical device development, including surgical robotics and FDA-regulated product launches.
MC
Martin C StammerChief Financial Officer.
DA
David A GiffininVice President, Human Resources2007–2017David Giffin is Vice President of Human Resources at Stereotaxis, a developer of robotic systems for interventional medicine. He holds a B.S. in Psychology from Purdue University and an M.S. in Industrial Relations from the Krannert School of Business, and brings extensive HR leadership experience across manufacturing, healthcare, medical device, and other industries.
FJ
Frank J. ChenginSVP, Worldwide Commercialization & Operations2010–2016Frank Cheng has held senior commercial and executive leadership roles across medical device companies for three decades, including positions at GE Healthcare in diagnostics imaging, Hillrom, Roche Diagnostics, and most notably seven years as Senior Vice President of worldwide commercialization at Stereotaxis, the publicly-traded robotic surgery company. He later served as President and Chief Commercial Officer at Eyenuk before becoming CEO of Caristo in 2023.
DF
David FischelinChairman & CEO
Board
RB
Ross B. LevinBoard director
FA
NF
Nathan FischelBoard director
NS
Nachum ShamirBoard director
MC
Myriam CuretBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$52M disclosed across 3 rounds · 2016–2024
▶$3MraisedAug 2024 · 1 investors · Other TechnologyRule 506(b)
▶$3MraisedAug 2024 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Nathan FischelDirector
- Nachum ShamirDirector
- David L. FischelExecutive Officer, Director
- Ross B. LevinDirector
- Myriam CuretDirector
- David W. BenferDirector
- Arun S. MenawatDirector
- Kimberly R. PeeryExecutive Officer, Director
- Amount sold
- $3M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedAug 2019 · 6 investors · Other TechnologyRule 506(b)
▶$25MraisedAug 2019 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- David L. FischelExecutive Officer, Director
- Martin C. StammerExecutive Officer
- Kevin M. BarryExecutive Officer
- David W. BenferDirector
- Nathan FischelDirector
- Joe KianiDirector
- Ross LevinDirector
- Arun S. MenawatDirector
- Robert J. MesseyDirector
- Offering amount
- $25M
- Amount sold
- $25M
- Placement agents
- Cowen and Company LLC
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24MraisedOct 2016 · 12 investors · Other TechnologyRule 506(b)
▶$24MraisedOct 2016 · 12 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Duane DeSistoDirector
- Arun MenawatDirector
- David W. BenferDirector
- David FischelDirector
- Robert J. MesseyDirector
- Eric N PrystowskyDirector
- Joseph KianiDirector
- Paul A. BrathwaiteExecutive Officer
- Martin C StammerExecutive Officer
- Fred A. MiddletonDirector
- David A GiffinExecutive Officer
- Frank J. ChengExecutive Officer
- Karen Witte DurosExecutive Officer
- William C. Mills IIIExecutive Officer, Director
- Offering amount
- $24M
- Amount sold
- $24M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Boston Scientific31 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Rf Surgical26 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Companies competing with Stereotaxis NASDAQ: STXS www.stereotaxis.com for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Stereotaxis (STXS) Stock Sees Little Reward For Recurring Revenue Progress - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Stereotaxis NASDAQ: STXS www.stereotaxis.com do?
- Stereotaxis develops robotic systems for interventional medicine, focused on endovascular and cardiac procedures such as cardiac ablation. Its technology serves physicians and hospitals performing minimally invasive interventional treatments.
- Who are Stereotaxis NASDAQ: STXS www.stereotaxis.com's investors?
- Stereotaxis NASDAQ: STXS www.stereotaxis.com's investors include Sanderling Ventures, Supernova Invest.
- How much funding has Stereotaxis NASDAQ: STXS www.stereotaxis.com raised?
- Stereotaxis NASDAQ: STXS www.stereotaxis.com has disclosed $52M raised across 3 rounds.
- Where is Stereotaxis NASDAQ: STXS www.stereotaxis.com headquartered?
- Stereotaxis NASDAQ: STXS www.stereotaxis.com is headquartered in Saint Louis, US.